Breaking News

InSphero, Charles River in PDX Pact

Alliance expands in vitro oncology services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

InSphero AG and Charles River Labs have entered a partnership under which Charles River will license its collection of patient-derived xenograft (PDX) tumors to InSphero, and Charles River will leverage InSphero’s 3D cell culture technology to extend its preclinical services using in vitro 3D InSight Tumor Microtissues derived from its existing PDX collection. In vitro 3D solutions enable the evaluation of a compound’s potency compared to standard-of-care drugs. This in vitro testing provides...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters